E#`}Gs XU 6 +B/6_BF =YEP;|x=rP( L?3gF V oO6jm V4o+^:rH# 9A[7De7aR[RD Df/^ &-8hx&y&- KR @wMt-WM_ U!-b w^9d}[^Zuw^zwd/a7w( uvTvq @CM[`G@ ?zCYax-z``- t1MT1?|k$@?ktt |\t;_-o\HGo \1u%1__L Ep@@M2@@,. Wi0 (i3sD?3 CY Q@n wF3 c^rr{ fKf:Inon ;p /f[U w6NeG #/M gpuzuwku- (B G-A) /3q]? G4a.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/gb,Tmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.